Ameer Kabour, MD
Cardiovascular Disease · Appleton, WINPI 1861485104
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,074 of the $16,248 with a category attached, or 86.6%. It is spread thinly across 51 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,954 and has fallen 90.6% since, to $374 in 2025. Among cardiovascular disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 601 payments — averaging $27.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Johnson & Johnson$2K
- Abbott$1K
- AstraZeneca$1K
- Novartis$1K
- Boehringer Ingelheim$891
- plus $7K from 45 others
Across 633 payments — averaging $1661.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$329K
- Novartis$214K
- Medtronic$156K
- Biotronik Inc.$102K
- Impulse Dynamics (USA) Inc.$102K
- Elutia, Inc.$65K
- plus $83K from 7 others
What the payments were for
- Travel & lodging$1,93112%
- Food & beverage$14,07487%
- Education$2431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$923
- Xience V coronary stent system$727
- CoreValve Evolut$378
- JARDIANCE$348
- XARELTO$324
- NEXLIZET$250
- NEXLETOL$250
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$250
- Assure WCD$216
- Saxenda$155
- MitraClip$152
- Impella$137
- WATCHMAN FLX$127
- ATRICURE SYNERGY ABLATION SYSTEM$125
- ATRICURE CRYOSURGICAL SYSTEM$125
- Launcher$123
- ZIO XT Patch$120
- Vascepa$105
- INVOKANA$104
- ELIQUIS$100
How this compares
$16,248 in reported general payments places this provider in the 90th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 269 | $252,222 |
| XareltoRivaroxaban | 62 | $57,932 |
| EntrestoSacubitril/Valsartan | 32 | $32,067 |
| Repatha SureclickEvolocumab | 36 | $27,648 |
| BrilintaTicagrelor | 26 | $24,032 |
| JardianceEmpagliflozin | 11 | $7,400 |
| Ranolazine ErRanolazine | 36 | $4,464 |
| Metoprolol Succinate | 264 | $4,030 |
| ClopidogrelClopidogrel Bisulfate | 322 | $3,928 |
| Atorvastatin Calcium | 225 | $2,856 |
| Metoprolol Tartrate | 353 | $2,470 |
| Losartan Potassium | 162 | $2,105 |
| Lisinopril | 160 | $1,586 |
| Rosuvastatin Calcium | 92 | $1,400 |
| Flecainide Acetate | 32 | $1,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $585 | $252,222269 claims |
| Johnson & JohnsonXarelto | $1,884 | $57,93262 claims |
| NovartisEntresto | $1,065 | $32,06732 claims |
| AstraZenecaBrilinta | $1,124 | $24,03226 claims |
| Boehringer IngelheimJardiance | $891 | $7,40011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Appleton
- Oleg ChebotarevAppleton$22K
- Kevin ChenAppleton$20K
- Abdulmohsin AhmadjeeAppleton$15K
- Agei EnohAppleton$9K
- Richard Santa CruzAppleton$9K
- Dong Bo YuAppleton$7K
- Jagdeep SabharwalAppleton$6K
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.